A novel transmembrane CXCR4 variant that expands the WHIM genotype-phenotype paradigm.
作者信息
Zmajkovicova Katarina, Pawar Sumit, Sharapova Svetlana O, Geier Christoph B, Wiest Ivana, Nguyen Chi, Monticelli Halenya, Maier-Munsa Sabine, Chen Kelly, Sleasman John W, Aleshkevich Svetlana, Polyakova Ekaterina, Sakovich Inga, Warnatz Klaus, Grimbacher Bodo, Proietti Michele, Sondheimer Neal, Ujhazi Boglarka, Gordon Sumai, Ellison Maryssa, Yilmaz Melis, Walter Jolan E, Badarau Adriana, Taveras Arthur G, Neff Jadee L, Bledsoe Jacob R, Tarrant Teresa K
机构信息
X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria.
Formerly X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria.
出版信息
Blood Adv. 2024 Jul 23;8(14):3754-3759. doi: 10.1182/bloodadvances.2023011875.
Abstract
摘要
相似文献
1
A novel transmembrane CXCR4 variant that expands the WHIM genotype-phenotype paradigm.
Blood Adv. 2024 Jul 23;8(14):3754-3759. doi: 10.1182/bloodadvances.2023011875.
2
Genotype-phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4 variants.
Genes Immun. 2022 Sep;23(6):196-204. doi: 10.1038/s41435-022-00181-9. Epub 2022 Sep 12.
3
Expanding CXCR4 variant landscape in WHIM syndrome: integrating clinical and functional data for variant interpretation.
Front Immunol. 2024 Jul 8;15:1411141. doi: 10.3389/fimmu.2024.1411141. eCollection 2024.
4
The complex nature of CXCR4 mutations in WHIM syndrome.
Front Immunol. 2024 Jul 5;15:1406532. doi: 10.3389/fimmu.2024.1406532. eCollection 2024.
5
The negative charge of the 343 site is essential for maintaining physiological functions of CXCR4.
BMC Mol Cell Biol. 2021 Jan 23;22(1):8. doi: 10.1186/s12860-021-00347-9.
6
WHIM Syndrome-linked CXCR4 mutations drive osteoporosis.
Nat Commun. 2023 Apr 12;14(1):2058. doi: 10.1038/s41467-023-37791-4.
7
Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice.
JCI Insight. 2019 Dec 19;4(24):132140. doi: 10.1172/jci.insight.132140.
8
Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4.
J Biol Chem. 2022 Feb;298(2):101551. doi: 10.1016/j.jbc.2021.101551. Epub 2021 Dec 30.
9
The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse.
Blood. 2013 Aug 1;122(5):666-73. doi: 10.1182/blood-2012-10-461830. Epub 2013 Jun 21.
10
Aberrant CXCR4 Signaling at Crossroad of WHIM Syndrome and Waldenstrom's Macroglobulinemia.
Int J Mol Sci. 2020 Aug 8;21(16):5696. doi: 10.3390/ijms21165696.
引用本文的文献
1
Case Report: A novel CXCR4 variant (p.S341Y) in a family with a pathogenic NFKB1 variant and variable clinical manifestations.
Front Immunol. 2025 Aug 20;16:1641122. doi: 10.3389/fimmu.2025.1641122. eCollection 2025.
2
The polygenic architecture of hidradenitis suppurativa reveals signaling mechanisms that implicate epithelial remodeling.
medRxiv. 2025 Jul 28:2025.07.25.25332168. doi: 10.1101/2025.07.25.25332168.
3
European guidelines on treatment and supportive measures in chronic neutropenias: A consensus between the European Hematology Association and the EuNet-INNOCHRON COST Action based on a systematic evidence review.
Hemasphere. 2025 Apr 16;9(4):e70113. doi: 10.1002/hem3.70113. eCollection 2025 Apr.
4
Clinicopathologic Features and the Spectrum of Myelokathexis in Warts, Hypogammaglobulinemia, Infections, Myelokathexis Syndrome.
Lab Invest. 2025 Apr 14;105(8):104174. doi: 10.1016/j.labinv.2025.104174.
5
Heterogeneous phenotype of a Chinese Familial WHIM syndrome with CXCR4 gain-of-function mutation.
Front Immunol. 2024 Nov 7;15:1460990. doi: 10.3389/fimmu.2024.1460990. eCollection 2024.
6
The complex nature of CXCR4 mutations in WHIM syndrome.
Front Immunol. 2024 Jul 5;15:1406532. doi: 10.3389/fimmu.2024.1406532. eCollection 2024.
本文引用的文献
1
Genotype-phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4 variants.
Genes Immun. 2022 Sep;23(6):196-204. doi: 10.1038/s41435-022-00181-9. Epub 2022 Sep 12.
2
Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients.
J Clin Immunol. 2022 Nov;42(8):1748-1765. doi: 10.1007/s10875-022-01312-7. Epub 2022 Aug 10.
3
Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
Blood. 2020 Dec 24;136(26):2994-3003. doi: 10.1182/blood.2020007197.
4
Common activation mechanism of class A GPCRs.
Elife. 2019 Dec 19;8:e50279. doi: 10.7554/eLife.50279.
5
WHIM Syndrome: from Pathogenesis Towards Personalized Medicine and Cure.
J Clin Immunol. 2019 Aug;39(6):532-556. doi: 10.1007/s10875-019-00665-w. Epub 2019 Jul 16.
6
Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4.
Front Immunol. 2019 Jun 5;10:1262. doi: 10.3389/fimmu.2019.01262. eCollection 2019.
7
Allosteric Na-binding site modulates CXCR4 activation.
Phys Chem Chem Phys. 2018 Oct 3;20(38):24915-24920. doi: 10.1039/c8cp04134b.
8
CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease.
Eur J Clin Invest. 2018 Nov;48 Suppl 2(Suppl Suppl 2):e12949. doi: 10.1111/eci.12949. Epub 2018 May 23.
9
Universality of the Sodium Ion Binding Mechanism in Class A G-Protein-Coupled Receptors.
Angew Chem Int Ed Engl. 2018 Mar 12;57(12):3048-3053. doi: 10.1002/anie.201708889. Epub 2018 Feb 22.
10
Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine.
Science. 2015 Mar 6;347(6226):1117-22. doi: 10.1126/science.1261064. Epub 2015 Jan 22.
Zotero 插件